{ "instance": { "zyme-20200630.htm": { "axisCustom": 0, "axisStandard": 16, "contextCount": 153, "dts": { "calculationLink": { "local": [ "zyme-20200630_cal.xml" ] }, "definitionLink": { "local": [ "zyme-20200630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "zyme-20200630.htm" ] }, "labelLink": { "local": [ "zyme-20200630_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "zyme-20200630_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "zyme-20200630.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 379, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 3, "http://www.zymeworks.com/20200630": 1, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 9 }, "keyCustom": 40, "keyStandard": 274, "memberCustom": 22, "memberStandard": 19, "nsprefix": "zyme", "nsuri": "http://www.zymeworks.com/20200630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.zymeworks.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105104 - Disclosure - Net loss per share", "role": "http://www.zymeworks.com/role/Netlosspershare", "shortName": "Net loss per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108105 - Disclosure - Investments", "role": "http://www.zymeworks.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110106 - Disclosure - IPR&D and Goodwill", "role": "http://www.zymeworks.com/role/IPRDandGoodwill", "shortName": "IPR&D and Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112107 - Disclosure - Liabilities", "role": "http://www.zymeworks.com/role/Liabilities", "shortName": "Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117108 - Disclosure - Shareholders' Equity", "role": "http://www.zymeworks.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123109 - Disclosure - Research, Collaboration and Licensing Agreements", "role": "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreements", "shortName": "Research, Collaboration and Licensing Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127110 - Disclosure - Other income (expenses), net", "role": "http://www.zymeworks.com/role/Otherincomeexpensesnet", "shortName": "Other income (expenses), net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130111 - Disclosure - Leases", "role": "http://www.zymeworks.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136112 - Disclosure - Financial Instruments", "role": "http://www.zymeworks.com/role/FinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2142113 - Disclosure - Commitments and Contingencies", "role": "http://www.zymeworks.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.zymeworks.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Net loss per share (Tables)", "role": "http://www.zymeworks.com/role/NetlosspershareTables", "shortName": "Net loss per share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313302 - Disclosure - Liabilities (Tables)", "role": "http://www.zymeworks.com/role/LiabilitiesTables", "shortName": "Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318303 - Disclosure - Shareholders' Equity (Tables)", "role": "http://www.zymeworks.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324304 - Disclosure - Research, Collaboration and Licensing Agreements (Tables)", "role": "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsTables", "shortName": "Research, Collaboration and Licensing Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328305 - Disclosure - Other expenses, net (Tables)", "role": "http://www.zymeworks.com/role/OtherexpensesnetTables", "shortName": "Other expenses, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "zyme:ScheduleOfLeaseLiabilitiesClassificationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331306 - Disclosure - Leases (Tables)", "role": "http://www.zymeworks.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "zyme:ScheduleOfLeaseLiabilitiesClassificationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2337307 - Disclosure - Financial Instruments (Tables)", "role": "http://www.zymeworks.com/role/FinancialInstrumentsTables", "shortName": "Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i759efd0fa6244b4db45c40443f113f22_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407401 - Disclosure - Net loss per share - Summary of Calculation of Diluted Loss Per Share (Detail)", "role": "http://www.zymeworks.com/role/NetlosspershareSummaryofCalculationofDilutedLossPerShareDetail", "shortName": "Net loss per share - Summary of Calculation of Diluted Loss Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i54d8a35bf4cc45a49ace979bd7d303b1_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CommercialPaper", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Investments - Additional Information (Detail)", "role": "http://www.zymeworks.com/role/InvestmentsAdditionalInformationDetail", "shortName": "Investments - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i54d8a35bf4cc45a49ace979bd7d303b1_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CommercialPaper", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesOutstanding", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.zymeworks.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - IPR&D and Goodwill Intangible Assets and Goodwill - Additional Information (Detail)", "role": "http://www.zymeworks.com/role/IPRDandGoodwillIntangibleAssetsandGoodwillAdditionalInformationDetail", "shortName": "IPR&D and Goodwill Intangible Assets and Goodwill - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:NumberOfReportingUnits", "reportCount": 1, "unique": true, "unitRef": "reporting_unit", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableTradeCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414404 - Disclosure - Liabilities - Schedule of Accounts Payable and Accrued Expenses (Detail)", "role": "http://www.zymeworks.com/role/LiabilitiesScheduleofAccountsPayableandAccruedExpensesDetail", "shortName": "Liabilities - Schedule of Accounts Payable and Accrued Expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableTradeCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415405 - Disclosure - Liabilities - Schedule of Other Current Liabilities (Detail)", "role": "http://www.zymeworks.com/role/LiabilitiesScheduleofOtherCurrentLiabilitiesDetail", "shortName": "Liabilities - Schedule of Other Current Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416406 - Disclosure - Liabilities - Schedule of Other Long-term Liabilities (Detail)", "role": "http://www.zymeworks.com/role/LiabilitiesScheduleofOtherLongtermLiabilitiesDetail", "shortName": "Liabilities - Schedule of Other Long-term Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i94e321b74fd0443e8b5899af05551f13_I20200127", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419407 - Disclosure - Shareholders' Equity - Additional Information (Detail)", "role": "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail", "shortName": "Shareholders' Equity - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i94e321b74fd0443e8b5899af05551f13_I20200127", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "id967d16dcf7a450aa2287562da8cda1c_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420408 - Disclosure - Shareholders' Equity - Summary of Stock Options Granted (Detail)", "role": "http://www.zymeworks.com/role/ShareholdersEquitySummaryofStockOptionsGrantedDetail", "shortName": "Shareholders' Equity - Summary of Stock Options Granted (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i198185eb7a85400f87b529cb87c9fc76_D20200101-20200630", "decimals": "2", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "cadPerShare", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "iaea757b78f6a41e1a774b6ab5b2db4dd_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421409 - Disclosure - Shareholders' Equity - Schedule of Stock-based Compensation Expense for Equity Classified Instruments (Detail)", "role": "http://www.zymeworks.com/role/ShareholdersEquityScheduleofStockbasedCompensationExpenseforEquityClassifiedInstrumentsDetail", "shortName": "Shareholders' Equity - Schedule of Stock-based Compensation Expense for Equity Classified Instruments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i2a70f156e43c4218bc76c82cc2826ab3_D20200401-20200630", "decimals": "-3", "lang": "en-US", "name": "zyme:AllocatedShareBasedCompensationExpenseIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i314cf67c451d42968ef4c3e121508829_D20200101-20200630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422410 - Disclosure - Shareholders' Equity - Schedule of Estimated Fair Value of Stock Options Assumptions (Detail)", "role": "http://www.zymeworks.com/role/ShareholdersEquityScheduleofEstimatedFairValueofStockOptionsAssumptionsDetail", "shortName": "Shareholders' Equity - Schedule of Estimated Fair Value of Stock Options Assumptions (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i314cf67c451d42968ef4c3e121508829_D20200101-20200630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i759efd0fa6244b4db45c40443f113f22_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425411 - Disclosure - Research, Collaboration and Licensing Agreements - Schedule Of Collaborative Arrangements and Noncollaborative Arrangement Transactions (Detail)", "role": "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsScheduleOfCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetail", "shortName": "Research, Collaboration and Licensing Agreements - Schedule Of Collaborative Arrangements and Noncollaborative Arrangement Transactions (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i43cff7b04387451c9c1e2ca2552c9f3f_D20200401-20200630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i759efd0fa6244b4db45c40443f113f22_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426412 - Disclosure - Research, Collaboration and Licensing Agreements - Additional Information - Strategic Partnership Revenue (Detail)", "role": "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail", "shortName": "Research, Collaboration and Licensing Agreements - Additional Information - Strategic Partnership Revenue (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i50ea1daa4f50462e9af25780c8523d90_I20191231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i759efd0fa6244b4db45c40443f113f22_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Loss and Comprehensive Loss", "role": "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Loss and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i759efd0fa6244b4db45c40443f113f22_D20200401-20200630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i759efd0fa6244b4db45c40443f113f22_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429413 - Disclosure - Other expenses, net (Details)", "role": "http://www.zymeworks.com/role/OtherexpensesnetDetails", "shortName": "Other expenses, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i759efd0fa6244b4db45c40443f113f22_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432414 - Disclosure - Leases - Additional Information (Detail)", "role": "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail", "shortName": "Leases - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "zyme:ScheduleOfLeaseLiabilitiesClassificationTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433415 - Disclosure - Leases - Schedule of Balance Sheet Classification of Lease Liabilities (Detail)", "role": "http://www.zymeworks.com/role/LeasesScheduleofBalanceSheetClassificationofLeaseLiabilitiesDetail", "shortName": "Leases - Schedule of Balance Sheet Classification of Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "zyme:ScheduleOfLeaseLiabilitiesClassificationTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "-3", "lang": "en-US", "name": "zyme:LeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434416 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Detail)", "role": "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail", "shortName": "Leases - Schedule of Maturities of Operating Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435417 - Disclosure - Leases - Schedule of Maturities of Finance Lease Liabilities (Detail)", "role": "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofFinanceLeaseLiabilitiesDetail", "shortName": "Leases - Schedule of Maturities of Finance Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438418 - Disclosure - Financial Instruments - Schedule of Financial Liabilities Measured at Fair Value on a Recurring Basis (Detail)", "role": "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofFinancialLiabilitiesMeasuredatFairValueonaRecurringBasisDetail", "shortName": "Financial Instruments - Schedule of Financial Liabilities Measured at Fair Value on a Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i49b7cf07c7ac46a687eb1c4ecea05bfc_I20200630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i50ea1daa4f50462e9af25780c8523d90_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439419 - Disclosure - Financial Instruments - Schedule of Changes in Fair Value of Liability Classified Stock Options (Detail)", "role": "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofChangesinFairValueofLiabilityClassifiedStockOptionsDetail", "shortName": "Financial Instruments - Schedule of Changes in Fair Value of Liability Classified Stock Options (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "zyme:ScheduleOfChangeInFairValueOfLiabilityClassifiedStockOptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i134616d063ec4defaf9d567ddeeb0554_I20200331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "zyme:ChangesInFairValueOfContingentConsiderationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i86d8bcf5731e44fdaece3c30d196684d_I20200331", "decimals": "-3", "first": true, "lang": "en-US", "name": "zyme:ContingentConsiderationLiabilityFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440420 - Disclosure - Financial Instruments - Summary of Changes in Fair Value of the Company's Liability for Contingent Consideration (Detail)", "role": "http://www.zymeworks.com/role/FinancialInstrumentsSummaryofChangesinFairValueoftheCompanysLiabilityforContingentConsiderationDetail", "shortName": "Financial Instruments - Summary of Changes in Fair Value of the Company's Liability for Contingent Consideration (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "zyme:ChangesInFairValueOfContingentConsiderationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i86d8bcf5731e44fdaece3c30d196684d_I20200331", "decimals": "-3", "first": true, "lang": "en-US", "name": "zyme:ContingentConsiderationLiabilityFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441421 - Disclosure - Financial Instruments - Narrative (Details)", "role": "http://www.zymeworks.com/role/FinancialInstrumentsNarrativeDetails", "shortName": "Financial Instruments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i93f056474b124ef4a2c8b5418e2889a9_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443422 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.zymeworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i056d3469bda348f5b6a67373a8507a6d_I20181231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statement of Changes in Shareholders' Equity", "role": "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity", "shortName": "Condensed Consolidated Statement of Changes in Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "i4909098eb6924af59281575b931823c1_D20190101-20190331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": "-3", "lang": "en-US", "name": "zyme:DepreciationAndAmortizationOnPropertyAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Nature of Operations", "role": "http://www.zymeworks.com/role/NatureofOperations", "shortName": "Nature of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.zymeworks.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104103 - Disclosure - Recent Accounting Pronouncements", "role": "http://www.zymeworks.com/role/RecentAccountingPronouncements", "shortName": "Recent Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "span", "div", "body", "html" ], "baseRef": "zyme-20200630.htm", "contextRef": "ie9e176fdabd24b7ab711419eee68e597_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 41, "tag": { "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "currency_CAD": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Canada, Dollars", "terseLabel": "Canada, Dollars" } } }, "localname": "CAD", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "currency_USD": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "United States of America, Dollars", "terseLabel": "United States of America, Dollars" } } }, "localname": "USD", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r241" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r91" ], "lang": { "en-US": { "role": { "label": "Director [Member]", "terseLabel": "Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r90", "r130", "r135", "r233" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail", "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsScheduleOfCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail", "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsScheduleOfCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r88", "r130", "r133", "r230", "r231" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail", "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsScheduleOfCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail", "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsScheduleOfCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r69", "r70", "r71", "r72" ], "lang": { "en-US": { "role": { "label": "Restatement Adjustment [Member]", "terseLabel": "After Amendment" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restatement [Axis]", "terseLabel": "Restatement [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restatement [Domain]", "terseLabel": "Restatement [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r70", "r71", "r72" ], "lang": { "en-US": { "role": { "label": "Previously Reported [Member]", "terseLabel": "Prior to Amendment" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r99" ], "lang": { "en-US": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r89", "r130", "r134", "r232", "r235", "r236" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r121", "r207" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r91", "r206" ], "lang": { "en-US": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "stpr_CA-BC": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "BRITISH COLUMBIA", "terseLabel": "BRITISH COLUMBIA" } } }, "localname": "CA-BC", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]", "terseLabel": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.zymeworks.com/role/LiabilitiesScheduleofAccountsPayableandAccruedExpensesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities (note 7)", "totalLabel": "Total" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets", "http://www.zymeworks.com/role/LiabilitiesScheduleofAccountsPayableandAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r27" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/Liabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r6", "r26" ], "calculation": { "http://www.zymeworks.com/role/LiabilitiesScheduleofAccountsPayableandAccruedExpensesDetail": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Trade payables" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LiabilitiesScheduleofAccountsPayableandAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r1", "r13", "r92", "r93", "r131" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable", "verboseLabel": "Maximum exposure for credit risk for accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets", "http://www.zymeworks.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r39", "r40", "r41" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r38", "r41", "r42", "r180" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Indefinite-lived Intangible Assets [Line Items]", "terseLabel": "Acquired Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredIndefiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/IPRDandGoodwillIntangibleAssetsandGoodwillAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r14" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Items not involving cash:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r140", "r142", "r167", "r168" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r142", "r161", "r166" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Compensation charge" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail", "http://www.zymeworks.com/role/ShareholdersEquityScheduleofStockbasedCompensationExpenseforEquityClassifiedInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r19", "r94", "r102" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Bad debt provision" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r58", "r109", "r112" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r87", "r212", "r222" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r2", "r3", "r35" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r96", "r103" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-sale, Noncurrent", "terseLabel": "Securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r143", "r163" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofChangesinFairValueofLiabilityClassifiedStockOptionsDetail", "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofFinancialLiabilitiesMeasuredatFairValueonaRecurringBasisDetail", "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail", "http://www.zymeworks.com/role/ShareholdersEquityScheduleofEstimatedFairValueofStockOptionsAssumptionsDetail", "http://www.zymeworks.com/role/ShareholdersEquityScheduleofStockbasedCompensationExpenseforEquityClassifiedInstrumentsDetail", "http://www.zymeworks.com/role/ShareholdersEquitySummaryofStockOptionsGrantedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r116" ], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Building" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r174", "r175" ], "calculation": { "http://www.zymeworks.com/role/LiabilitiesScheduleofOtherLongtermLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "verboseLabel": "Liability for contingent consideration (note 12)" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LiabilitiesScheduleofOtherLongtermLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r61", "r62", "r63" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Acquisition of property and equipment in accounts payable and accrued liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r0", "r22", "r60" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r55", "r60", "r64" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r55", "r189" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r66" ], "lang": { "en-US": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Warrant exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r176", "r177", "r179" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Research, Collaboration and Licensing Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail", "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsScheduleOfCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaper": { "auth_ref": [ "r9", "r213", "r223" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.", "label": "Commercial Paper", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaper", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r33", "r120", "r218", "r227" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (note 13)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r119", "r122" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common shares" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity", "http://www.zymeworks.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r12", "r123" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r12" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common shares, no par value; unlimited authorized shares at June\u00a030, 2020 and December\u00a031, 2019, respectively; 45,563,155 and 39,564,529 shares issued and outstanding at June\u00a030, 2020 and December\u00a031, 2019, respectively (note 8b)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r126", "r128", "r131" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "terseLabel": "Contract assets" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r126", "r127", "r131" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "verboseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r126", "r127", "r131" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Long-term portion of deferred revenue (note 9)" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r132" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Performance obligation recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r48" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r172" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax asset" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r171", "r172" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Maximum amount the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount", "terseLabel": "Purchase of shares under ESPP, maximum limit for each employee" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r36", "r37", "r181", "r210" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "periodEndLabel": "Liability at end of the period", "periodStartLabel": "Liability at beginning of the period", "terseLabel": "Fair value of liability classified options (note 12)" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets", "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofChangesinFairValueofLiabilityClassifiedStockOptionsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net loss per common share (note 4):" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r74" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic and diluted (in dollars per share)", "verboseLabel": "Net loss per common share-basic and diluted (in dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss", "http://www.zymeworks.com/role/NetlosspershareSummaryofCalculationofDilutedLossPerShareDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r76" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net loss per share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/Netlosspershare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r189" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.zymeworks.com/role/LiabilitiesScheduleofAccountsPayableandAccruedExpensesDetail": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee compensation and vacation accruals" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LiabilitiesScheduleofAccountsPayableandAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofChangesinFairValueofLiabilityClassifiedStockOptionsDetail", "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofFinancialLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r182", "r183", "r184", "r185" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofChangesinFairValueofLiabilityClassifiedStockOptionsDetail", "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofFinancialLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r137", "r138", "r139", "r183", "r208" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofFinancialLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r137", "r138", "r139", "r183", "r209" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofFinancialLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r182", "r183" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Financial Liabilities Measured at Fair Value on a Recurring Basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofFinancialLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r192", "r203" ], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofBalanceSheetClassificationofLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "zyme_LeaseLiability", "weight": 1.0 }, "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofFinanceLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Finance lease liabilities", "totalLabel": "Total finance lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofBalanceSheetClassificationofLeaseLiabilitiesDetail", "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofFinanceLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r192" ], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofBalanceSheetClassificationofLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 }, "http://www.zymeworks.com/role/LiabilitiesScheduleofOtherCurrentLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Current portion included in other current liabilities", "verboseLabel": "Current portion of finance lease liability (note 11)" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofBalanceSheetClassificationofLeaseLiabilitiesDetail", "http://www.zymeworks.com/role/LiabilitiesScheduleofOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Finance Lease Liabilities" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r192" ], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofBalanceSheetClassificationofLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 }, "http://www.zymeworks.com/role/LiabilitiesScheduleofOtherLongtermLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance lease liability (note 11)", "verboseLabel": "Long-term portion included in other long-term liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofBalanceSheetClassificationofLeaseLiabilitiesDetail", "http://www.zymeworks.com/role/LiabilitiesScheduleofOtherLongtermLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r203" ], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofFinanceLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofFinanceLeaseLiabilitiesDetail_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total finance lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofFinanceLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths": { "auth_ref": [ "r203" ], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofFinanceLeaseLiabilitiesDetail_1": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Finance Lease, Liability, Payments, Due in Next Rolling Twelve Months", "terseLabel": "Within 1 year" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofFinanceLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive": { "auth_ref": [ "r203" ], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofFinanceLeaseLiabilitiesDetail_1": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Finance Lease, Liability, Payments, Due in Rolling Year Five", "terseLabel": "4 to 5 years" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofFinanceLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour": { "auth_ref": [ "r203" ], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofFinanceLeaseLiabilitiesDetail_1": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Finance Lease, Liability, Payments, Due in Rolling Year Four", "terseLabel": "3 to 4 years" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofFinanceLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree": { "auth_ref": [ "r203" ], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofFinanceLeaseLiabilitiesDetail_1": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Finance Lease, Liability, Payments, Due in Rolling Year Three", "terseLabel": "2 to 3 years" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofFinanceLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo": { "auth_ref": [ "r203" ], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofFinanceLeaseLiabilitiesDetail_1": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Finance Lease, Liability, Payments, Due in Rolling Year Two", "terseLabel": "1 to 2 years" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofFinanceLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r203" ], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofFinanceLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Imputed interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofFinanceLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r194", "r199" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedLabel": "Finance lease payments" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/FinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "terseLabel": "Financial liabilities measured at fair value" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofFinancialLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Financial Liabilities Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "FinancialLiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofFinancialLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r111" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r186", "r187", "r188" ], "calculation": { "http://www.zymeworks.com/role/OtherexpensesnetDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Foreign exchange (loss) gain" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/OtherexpensesnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r59", "r186", "r187", "r188" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Unrealized", "negatedLabel": "Unrealized foreign exchange (gain) loss" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r49" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expenses" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityScheduleofStockbasedCompensationExpenseforEquityClassifiedInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r104", "r106" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill (note 6)" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "IPR&D and Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/IPRDandGoodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r58", "r105", "r107", "r108" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "verboseLabel": "Goodwill impairment loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/IPRDandGoodwillIntangibleAssetsandGoodwillAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r58", "r114" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Impairment on acquired IPR&D" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss", "http://www.zymeworks.com/role/IPRDandGoodwillIntangibleAssetsandGoodwillAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r45", "r69", "r211", "r219", "r229" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r118" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityScheduleofStockbasedCompensationExpenseforEquityClassifiedInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityScheduleofStockbasedCompensationExpenseforEquityClassifiedInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r65", "r86", "r173" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax recovery (expense)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r57" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r57" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r57" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r57" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Deferred income tax expense" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxes": { "auth_ref": [ "r57" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.", "label": "Increase (Decrease) in Income Taxes", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in non-cash operating working capital:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r57" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r110", "r113" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/IPRDandGoodwillIntangibleAssetsandGoodwillAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r113" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Acquired in-process research and development (note 6)", "verboseLabel": "In-process research and development" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets", "http://www.zymeworks.com/role/IPRDandGoodwillIntangibleAssetsandGoodwillAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r110", "r113" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/IPRDandGoodwillIntangibleAssetsandGoodwillAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTextBlock": { "auth_ref": [ "r97", "r98", "r100", "r101" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for investment.", "label": "Investment [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, All Other Investments [Abstract]", "terseLabel": "Investments, All Other Investments [Abstract]" } } }, "localname": "InvestmentsAllOtherInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r198" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r203" ], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": { "auth_ref": [ "r203" ], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive": { "auth_ref": [ "r203" ], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five", "terseLabel": "4 to 5 years" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": { "auth_ref": [ "r203" ], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four", "terseLabel": "3 to 4 years" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": { "auth_ref": [ "r203" ], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three", "terseLabel": "2 to 3 years" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": { "auth_ref": [ "r203" ], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two", "terseLabel": "1 to 2 years" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": { "auth_ref": [ "r203" ], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months", "terseLabel": "Within 1 year" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r203" ], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Extension term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r29" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r18", "r214", "r225" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r23" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Long-term investments (note 5)" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r77", "r85" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of Operations" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/NatureofOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r55" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r55" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r55", "r56", "r59" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r43", "r44", "r46", "r59", "r75", "r220", "r228" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss and comprehensive loss", "verboseLabel": "Basic and diluted" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity", "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss", "http://www.zymeworks.com/role/NetlosspershareSummaryofCalculationofDilutedLossPerShareDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Net loss attributable to common shareholders:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/NetlosspershareSummaryofCalculationofDilutedLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r73" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "New Accounting Pronouncements and Changes in Accounting Principles [Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/RecentAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r50" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfReportingUnits": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.", "label": "Number of Reporting Units", "terseLabel": "Number of reporting units" } } }, "localname": "NumberOfReportingUnits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/IPRDandGoodwillIntangibleAssetsandGoodwillAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingCashFlowsDirectMethodAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Cash Flows, Direct Method [Abstract]", "terseLabel": "Operating Cash Flows, Direct Method [Abstract]" } } }, "localname": "OperatingCashFlowsDirectMethodAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r193" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseImpairmentLoss": { "auth_ref": [ "r190" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.", "label": "Operating Lease, Impairment Loss", "terseLabel": "Impairment loss" } } }, "localname": "OperatingLeaseImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due, Rolling Maturity [Abstract]", "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due, Rolling Maturity [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r192" ], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofBalanceSheetClassificationofLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "zyme_LeaseLiability", "weight": 1.0 }, "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities", "totalLabel": "Operating Lease, Liability, Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofBalanceSheetClassificationofLeaseLiabilitiesDetail", "http://www.zymeworks.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r192" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.zymeworks.com/role/LeasesScheduleofBalanceSheetClassificationofLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion", "verboseLabel": "Current portion of operating lease liability (note 11)" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets", "http://www.zymeworks.com/role/LeasesScheduleofBalanceSheetClassificationofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r192" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.zymeworks.com/role/LeasesScheduleofBalanceSheetClassificationofLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term portion", "verboseLabel": "Long-term portion of operating lease liability (note 11)" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets", "http://www.zymeworks.com/role/LeasesScheduleofBalanceSheetClassificationofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r195", "r199" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for measurement of operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r191" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r202", "r204" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r201", "r204" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.zymeworks.com/role/LiabilitiesScheduleofAccountsPayableandAccruedExpensesDetail": { "order": 5.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.", "label": "Other Accounts Payable and Accrued Liabilities", "terseLabel": "Other" } } }, "localname": "OtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LiabilitiesScheduleofAccountsPayableandAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of other current liabilities.", "label": "Other Current Liabilities [Table Text Block]", "terseLabel": "Schedule of Other Current Liabilities" } } }, "localname": "OtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r136", "r169" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other income (expenses), net" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/Otherincomeexpensesnet" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r4", "r5", "r30" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.zymeworks.com/role/LiabilitiesScheduleofOtherCurrentLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities (note 7)", "totalLabel": "Total" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets", "http://www.zymeworks.com/role/LiabilitiesScheduleofOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.zymeworks.com/role/LiabilitiesScheduleofOtherLongtermLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities (note 7)", "totalLabel": "Total" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets", "http://www.zymeworks.com/role/LiabilitiesScheduleofOtherLongtermLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Table Text Block]", "terseLabel": "Schedule of Other Long-term Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r51" ], "calculation": { "http://www.zymeworks.com/role/OtherexpensesnetDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Other Nonoperating Expense", "negatedLabel": "Other" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/OtherexpensesnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r50" ], "calculation": { "http://www.zymeworks.com/role/OtherexpensesnetDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income", "terseLabel": "Other" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/OtherexpensesnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r51" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://www.zymeworks.com/role/OtherexpensesnetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other (expenses) income, net (note 10)", "totalLabel": "Total other income and expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss", "http://www.zymeworks.com/role/OtherexpensesnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForProceedsFromInvestments": { "auth_ref": [ "r67" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.", "label": "Payments for (Proceeds from) Investments", "negatedLabel": "Net (purchases) redemptions of short-term and long-term investments" } } }, "localname": "PaymentsForProceedsFromInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r54" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Underwriting discounts, commissions and offering expenses" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r52" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Acquisition of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r52" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Acquisition of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r2", "r20", "r21" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseNoncurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.", "label": "Prepaid Expense, Noncurrent", "terseLabel": "Long-term prepaid assets" } } }, "localname": "PrepaidExpenseNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r53", "r164" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Issuance of common shares on exercise of stock options (note 8e)" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r53", "r164" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock options exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r24", "r117" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r7", "r8", "r117", "r226" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r7", "r116" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r170", "r237" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityScheduleofStockbasedCompensationExpenseforEquityClassifiedInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Share Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail", "http://www.zymeworks.com/role/ShareholdersEquityScheduleofStockbasedCompensationExpenseforEquityClassifiedInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r15", "r124", "r224" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r129", "r130" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Research and development collaborations (note 9)", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss", "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail", "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsScheduleOfCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r200", "r204" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Leased assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds from issuance" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares issued (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accounts Payable and Accrued Expenses" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable": { "auth_ref": [ "r110" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of major classes of indefinite-lived intangible assets acquired showing attributes such as amounts and totals. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. Indefinite-lived assets are assets that are not subject to amortization. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total.", "label": "Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table]", "terseLabel": "Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/IPRDandGoodwillIntangibleAssetsandGoodwillAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail", "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsScheduleOfCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]", "terseLabel": "Schedule of Revenue Recognized from Strategic Partnerships" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r75" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Summary of Calculation of Diluted Loss Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/NetlosspershareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r142", "r160", "r166" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Investments [Line Items]", "terseLabel": "Schedule of Investments [Line Items]" } } }, "localname": "ScheduleOfInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsTable": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.", "label": "Schedule of Investments [Table]", "terseLabel": "Schedule of Investments [Table]" } } }, "localname": "ScheduleOfInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Schedule of Other Nonoperating Income (Expense)" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/OtherexpensesnetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r143", "r163" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityScheduleofEstimatedFairValueofStockOptionsAssumptionsDetail", "http://www.zymeworks.com/role/ShareholdersEquityScheduleofStockbasedCompensationExpenseforEquityClassifiedInstrumentsDetail", "http://www.zymeworks.com/role/ShareholdersEquitySummaryofStockOptionsGrantedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r146", "r152", "r153" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Options Granted" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r155" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Estimated Fair Value of Stock Options Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r57" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Options granted under the new plan exerciseable period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r151" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Grants in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityScheduleofEstimatedFairValueofStockOptionsAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityScheduleofEstimatedFairValueofStockOptionsAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityScheduleofEstimatedFairValueofStockOptionsAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityScheduleofEstimatedFairValueofStockOptionsAssumptionsDetail", "http://www.zymeworks.com/role/ShareholdersEquityScheduleofStockbasedCompensationExpenseforEquityClassifiedInstrumentsDetail", "http://www.zymeworks.com/role/ShareholdersEquitySummaryofStockOptionsGrantedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Maximum eligible employees contribution under ESPP" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquitySummaryofStockOptionsGrantedDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquitySummaryofStockOptionsGrantedDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r163" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquitySummaryofStockOptionsGrantedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r148", "r163" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Number of options outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityScheduleofEstimatedFairValueofStockOptionsAssumptionsDetail", "http://www.zymeworks.com/role/ShareholdersEquitySummaryofStockOptionsGrantedDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquitySummaryofStockOptionsGrantedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquitySummaryofStockOptionsGrantedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquitySummaryofStockOptionsGrantedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Shares granted with respect to maximum fixed amount equal, percentage" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Description and Terms", "terseLabel": "Share-based compensation arrangement by share-based payment award, plan modification, description and terms" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r141", "r145" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofChangesinFairValueofLiabilityClassifiedStockOptionsDetail", "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofFinancialLiabilitiesMeasuredatFairValueonaRecurringBasisDetail", "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail", "http://www.zymeworks.com/role/ShareholdersEquityScheduleofEstimatedFairValueofStockOptionsAssumptionsDetail", "http://www.zymeworks.com/role/ShareholdersEquityScheduleofStockbasedCompensationExpenseforEquityClassifiedInstrumentsDetail", "http://www.zymeworks.com/role/ShareholdersEquitySummaryofStockOptionsGrantedDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquitySummaryofStockOptionsGrantedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquitySummaryofStockOptionsGrantedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquitySummaryofStockOptionsGrantedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r156", "r165" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected average life of options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityScheduleofEstimatedFairValueofStockOptionsAssumptionsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted- Average Contractual Term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquitySummaryofStockOptionsGrantedDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Remaining unamortized compensation expense, weighted-average period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Percentage of discounted purchase price of average market price" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Shares issue price (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r10", "r215", "r216", "r217", "r221" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments (note 5)" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r68" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r34", "r123" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r11", "r12", "r123", "r124" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common shares through employee share purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Number of shares issued to underwriters (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r11", "r12", "r123", "r124" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Issuance of common shares and warrants in connection with public offering (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r11", "r12", "r123", "r124", "r149" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Issuance of common shares on exercise of options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity", "http://www.zymeworks.com/role/ShareholdersEquitySummaryofStockOptionsGrantedDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r11", "r12", "r123", "r124" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common shares through employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r11", "r12", "r123", "r124" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common shares and pre-funded warrants in connection with public offering (Note 8)" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r34", "r123", "r124" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common shares on exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r12", "r16", "r17", "r95" ], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets", "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r125" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary or Equity Method Investee [Line Items]", "terseLabel": "Subsidiary or Equity Method Investee [Line Items]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing items:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r78", "r79", "r80", "r81", "r82", "r83", "r84" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeasePayment": { "auth_ref": [ "r196" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for variable lease payment excluded from lease liability.", "label": "Variable Lease, Payment", "terseLabel": "Variable lease payment" } } }, "localname": "VariableLeasePayment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss", "http://www.zymeworks.com/role/NetlosspershareSummaryofCalculationofDilutedLossPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted-average common shares outstanding (note 4):" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofLossandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Weighted-average common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zymeworks.com/role/NetlosspershareSummaryofCalculationofDilutedLossPerShareDetail" ], "xbrltype": "stringItemType" }, "zyme_AccruedLegalAndProfessionalFeesCurrent": { "auth_ref": [], "calculation": { "http://www.zymeworks.com/role/LiabilitiesScheduleofAccountsPayableandAccruedExpensesDetail": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued legal and professional fees, current.", "label": "Accrued Legal And Professional Fees, Current", "terseLabel": "Accrued legal and professional fees" } } }, "localname": "AccruedLegalAndProfessionalFeesCurrent", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/LiabilitiesScheduleofAccountsPayableandAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "zyme_AccruedResearchExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.zymeworks.com/role/LiabilitiesScheduleofAccountsPayableandAccruedExpensesDetail": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued research expenses, current.", "label": "Accrued Research Expenses Current", "terseLabel": "Accrued research expenses" } } }, "localname": "AccruedResearchExpensesCurrent", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/LiabilitiesScheduleofAccountsPayableandAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "zyme_AdjustmentsToAdditionalPaidInCapitalFairValueAdjustmentUponReclassificationOfStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Adjustments to additional paid in capital fair value adjustment upon reclassification of stock options.", "label": "Adjustments to Additional Paid in Capital Fair Value Adjustment Upon Reclassification of Stock Options", "terseLabel": "Fair value adjustments upon reclassification of options to liabilities" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalFairValueAdjustmentUponReclassificationOfStockOptions", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementofChangesinShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "zyme_AllocatedShareBasedCompensationExpenseIncome": { "auth_ref": [], "calculation": { "http://www.zymeworks.com/role/ShareholdersEquityScheduleofStockbasedCompensationExpenseforEquityClassifiedInstrumentsDetail": { "order": 1.0, "parentTag": "zyme_ShareBasedCompensationExpenseAndIncreaseDecreaseInFairValueOfLiabilityClassedEquityInstruments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Allocated share based compensation expense (income).", "label": "Allocated Share Based Compensation Expense Income", "terseLabel": "Stock-based compensation for equity classified instruments" } } }, "localname": "AllocatedShareBasedCompensationExpenseIncome", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityScheduleofStockbasedCompensationExpenseforEquityClassifiedInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "zyme_BeiGeneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bei Gene [Member]", "label": "Bei Gene [Member]", "terseLabel": "Bei Gene" } } }, "localname": "BeiGeneMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail", "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsScheduleOfCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetail" ], "xbrltype": "domainItemType" }, "zyme_BristolMyersSquibbMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bristol-Myers Squibb", "label": "Bristol-Myers Squibb [Member]", "terseLabel": "Bristol-Myers Squibb" } } }, "localname": "BristolMyersSquibbMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail", "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsScheduleOfCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetail" ], "xbrltype": "domainItemType" }, "zyme_CADDollarsUnderTheNewStockOptionPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CAD dollars under the new stock option plan.", "label": "CAD Dollars Under The New Stock Option Plan [Member]", "terseLabel": "Canadian Dollar Under the New Option Stock Plan" } } }, "localname": "CADDollarsUnderTheNewStockOptionPlanMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquitySummaryofStockOptionsGrantedDetail" ], "xbrltype": "domainItemType" }, "zyme_CanadianDollarUnderTheNewStockOptionPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Canadian Dollar Under The New Stock Option Plan", "label": "Canadian Dollar Under The New Stock Option Plan [Member]", "terseLabel": "Canadian Dollar Under the New Stock Option Plan" } } }, "localname": "CanadianDollarUnderTheNewStockOptionPlanMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityScheduleofEstimatedFairValueofStockOptionsAssumptionsDetail" ], "xbrltype": "domainItemType" }, "zyme_ChangesInFairValueOfContingentConsiderationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Changes In Fair Value Of Contingent Consideration [Table Text Block]", "label": "Changes In Fair Value Of Contingent Consideration [Table Text Block]", "terseLabel": "Summary of Changes in Fair Value of the Company's Liability for Contingent Consideration" } } }, "localname": "ChangesInFairValueOfContingentConsiderationTableTextBlock", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "zyme_CommercialLicenseOptionFeeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commercial License Option Fee", "label": "Commercial License Option Fee [Member]", "terseLabel": "Commercial license option fee" } } }, "localname": "CommercialLicenseOptionFeeMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail", "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsScheduleOfCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetail" ], "xbrltype": "domainItemType" }, "zyme_CommonStockSharesIssuableUponExerciseOfStockOption": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common stock shares issuable upon exercise of stock option.", "label": "Common Stock Shares Issuable Upon Exercise Of Stock Option", "terseLabel": "Shares issuable upon exercise of stock options (in shares)" } } }, "localname": "CommonStockSharesIssuableUponExerciseOfStockOption", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "zyme_ContingentConsiderationFairValueAdjustments": { "auth_ref": [], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contingent consideration fair value adjustments.", "label": "Contingent Consideration Fair Value Adjustments", "terseLabel": "Change in fair value of contingent consideration" } } }, "localname": "ContingentConsiderationFairValueAdjustments", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.zymeworks.com/role/FinancialInstrumentsSummaryofChangesinFairValueoftheCompanysLiabilityforContingentConsiderationDetail" ], "xbrltype": "monetaryItemType" }, "zyme_ContingentConsiderationLiabilityFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contingent Consideration Liability Fair Value Disclosure", "label": "Contingent Consideration Liability Fair Value Disclosure", "periodEndLabel": "Liability at end of the period", "periodStartLabel": "Liability at the beginning of the period" } } }, "localname": "ContingentConsiderationLiabilityFairValueDisclosure", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/FinancialInstrumentsSummaryofChangesinFairValueoftheCompanysLiabilityforContingentConsiderationDetail" ], "xbrltype": "monetaryItemType" }, "zyme_ContingentConsiderationLiabilityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contingent Consideration Liability", "label": "Contingent Consideration Liability [Roll Forward]", "terseLabel": "Contingent Consideration Liability [Roll Forward]" } } }, "localname": "ContingentConsiderationLiabilityRollForward", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/FinancialInstrumentsSummaryofChangesinFairValueoftheCompanysLiabilityforContingentConsiderationDetail" ], "xbrltype": "stringItemType" }, "zyme_ContributionsToEmployeeSharePurchasePlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "contributions to employee share purchase plan.", "label": "Contributions To Employee Share Purchase Plan", "terseLabel": "Total amount contributed by ESPP participants" } } }, "localname": "ContributionsToEmployeeSharePurchasePlan", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "zyme_DaiichiSankyoCoLtdMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Daiichi sankyo, co., ltd.", "label": "Daiichi Sankyo, Co., Ltd [Member]", "terseLabel": "Daiichi Sankyo, Co., Ltd" } } }, "localname": "DaiichiSankyoCoLtdMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail", "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsScheduleOfCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetail" ], "xbrltype": "domainItemType" }, "zyme_DeferredFinancingFee": { "auth_ref": [], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred financing fee.", "label": "Deferred Financing Fee", "terseLabel": "Deferred financing fees" } } }, "localname": "DeferredFinancingFee", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "zyme_DepreciationAndAmortizationOnPropertyAndEquipment": { "auth_ref": [], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Depreciation And Amortization On Property And Equipment", "label": "Depreciation And Amortization On Property And Equipment", "terseLabel": "Depreciation and amortization of property and equipment" } } }, "localname": "DepreciationAndAmortizationOnPropertyAndEquipment", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "zyme_DerivativeLiabilityRollForwardRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derivative Liability Roll Forward", "label": "Derivative Liability Roll Forward [Roll Forward]", "terseLabel": "Derivative Liability Roll Forward [Roll Forward]" } } }, "localname": "DerivativeLiabilityRollForwardRollForward", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofChangesinFairValueofLiabilityClassifiedStockOptionsDetail" ], "xbrltype": "stringItemType" }, "zyme_EliLillyAndCompanyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Eli lilly and company.", "label": "Eli Lilly And Company [Member]", "terseLabel": "Eli Lilly and Company" } } }, "localname": "EliLillyAndCompanyMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail", "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsScheduleOfCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetail" ], "xbrltype": "domainItemType" }, "zyme_EmployeesStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employees Stock Purchase Plan [Member]", "label": "Employees Stock Purchase Plan [Member]", "terseLabel": "Employees Stock Purchase Plan" } } }, "localname": "EmployeesStockPurchasePlanMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "zyme_ExerciseOfLiabilityClassifiedOptions": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Exercise of liability classified options.", "label": "Exercise of Liability Classified Options", "negatedLabel": "Exercise of options" } } }, "localname": "ExerciseOfLiabilityClassifiedOptions", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofChangesinFairValueofLiabilityClassifiedStockOptionsDetail" ], "xbrltype": "monetaryItemType" }, "zyme_FinanceExpenseIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finance expense (income).", "label": "Finance Expense (Income) [Member]", "terseLabel": "Finance Expense" } } }, "localname": "FinanceExpenseIncomeMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityScheduleofStockbasedCompensationExpenseforEquityClassifiedInstrumentsDetail" ], "xbrltype": "domainItemType" }, "zyme_FixedLeasePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fixed lease payment.", "label": "Fixed Lease Payment", "terseLabel": "Fixed lease payment" } } }, "localname": "FixedLeasePayment", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "zyme_IconicTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Iconic Therapeutics Inc [Member]", "terseLabel": "Iconic" } } }, "localname": "IconicTherapeuticsIncMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail", "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsScheduleOfCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetail" ], "xbrltype": "domainItemType" }, "zyme_IncreaseDecreaseInFairValueOfLiabilityClassifiedEquityInstruments": { "auth_ref": [], "calculation": { "http://www.zymeworks.com/role/ShareholdersEquityScheduleofStockbasedCompensationExpenseforEquityClassifiedInstrumentsDetail": { "order": 2.0, "parentTag": "zyme_ShareBasedCompensationExpenseAndIncreaseDecreaseInFairValueOfLiabilityClassedEquityInstruments", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase (decrease) in fair value of liability classified equity instruments.", "label": "Increase (decrease) in fair value of liability classified equity instruments", "negatedLabel": "Change in fair value of liability classified equity instruments" } } }, "localname": "IncreaseDecreaseInFairValueOfLiabilityClassifiedEquityInstruments", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityScheduleofStockbasedCompensationExpenseforEquityClassifiedInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "zyme_IncreaseDecreaseInFairValueOfLiabilityClassifiedStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase (decrease) in fair value of liability classified stock options.", "label": "Increase (decrease) in fair value of liability classified stock options", "terseLabel": "Increase (decrease) in fair value of liability classified stock options" } } }, "localname": "IncreaseDecreaseInFairValueOfLiabilityClassifiedStockOptions", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofChangesinFairValueofLiabilityClassifiedStockOptionsDetail" ], "xbrltype": "monetaryItemType" }, "zyme_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase decrease in operating lease liabilities.", "label": "Increase Decrease in Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "zyme_IndefiniteLivedIntangibleAssetsInProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of indefinite-lived intangible assets. In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "Indefinite Lived Intangible Assets In Process Research and Development [Member]", "terseLabel": "IPR&D" } } }, "localname": "IndefiniteLivedIntangibleAssetsInProcessResearchAndDevelopmentMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/IPRDandGoodwillIntangibleAssetsandGoodwillAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "zyme_InvestmentInterestPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Investment interest percentage.", "label": "Investment Interest Percentage", "terseLabel": "Investments interest rate" } } }, "localname": "InvestmentInterestPercentage", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "zyme_LeaseLiability": { "auth_ref": [], "calculation": { "http://www.zymeworks.com/role/LeasesScheduleofBalanceSheetClassificationofLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease Liability", "label": "Lease Liability", "totalLabel": "Total lease liabilities" } } }, "localname": "LeaseLiability", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/LeasesScheduleofBalanceSheetClassificationofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "zyme_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "terseLabel": "Future lease payments" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "zyme_LesseeOperatingLeaseNumberOfRenewalOptions": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Number Of Renewal Options", "label": "Lessee, Operating Lease, Number Of Renewal Options", "terseLabel": "Number of renewal options" } } }, "localname": "LesseeOperatingLeaseNumberOfRenewalOptions", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "zyme_LiabilityClassifiedStockOptionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Liability classified stock options.", "label": "Liability Classified Stock Options [Member]", "terseLabel": "Liability classified stock options" } } }, "localname": "LiabilityClassifiedStockOptionsMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofChangesinFairValueofLiabilityClassifiedStockOptionsDetail", "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofFinancialLiabilitiesMeasuredatFairValueonaRecurringBasisDetail", "http://www.zymeworks.com/role/ShareholdersEquityScheduleofEstimatedFairValueofStockOptionsAssumptionsDetail" ], "xbrltype": "domainItemType" }, "zyme_LiabilityForContingentConsiderationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Liability for contingent consideration.", "label": "Liability for Contingent Consideration [Member]", "terseLabel": "Liability for Contingent Consideration" } } }, "localname": "LiabilityForContingentConsiderationMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofFinancialLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "zyme_LiabilityForInLicensingAgreement": { "auth_ref": [], "calculation": { "http://www.zymeworks.com/role/LiabilitiesScheduleofOtherLongtermLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Liability For In-Licensing Agreement", "label": "Liability For In-Licensing Agreement", "terseLabel": "Liability for in-licensing agreement" } } }, "localname": "LiabilityForInLicensingAgreement", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/LiabilitiesScheduleofOtherLongtermLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "zyme_LicenseAgreementsResearchCollaborationsAndDevelopmentAgreementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "License Agreements Research Collaborations And Development Agreements [Abstract]", "label": "License Agreements Research Collaborations And Development Agreements [Abstract]", "terseLabel": "License Agreements Research Collaborations And Development Agreements [Abstract]" } } }, "localname": "LicenseAgreementsResearchCollaborationsAndDevelopmentAgreementsAbstract", "nsuri": "http://www.zymeworks.com/20200630", "xbrltype": "stringItemType" }, "zyme_LicensingAgreementNoncashConsideration": { "auth_ref": [], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Licensing Agreement, Noncash Consideration", "label": "Licensing Agreement, Noncash Consideration", "negatedLabel": "Non-cash consideration from licensing agreement" } } }, "localname": "LicensingAgreementNoncashConsideration", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "zyme_LongTermGuaranteedInvestmentCertificatesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term Guaranteed Investment Certificates", "label": "Long-term Guaranteed Investment Certificates [Member]", "terseLabel": "Long-term GICs" } } }, "localname": "LongTermGuaranteedInvestmentCertificatesMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "zyme_LongTermInvestmentsMaturityTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long Term Investments Maturity Term", "label": "Long Term Investments Maturity Term", "terseLabel": "Long-term investments maturity term" } } }, "localname": "LongTermInvestmentsMaturityTerm", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "zyme_MaximumNumberOfCommonSharesReservedForIssuance": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maximum number of common shares reserved for issuance under new plan.", "label": "Maximum Number Of Common Shares Reserved For Issuance", "terseLabel": "Maximum number of common shares reserved for issuance (in shares)" } } }, "localname": "MaximumNumberOfCommonSharesReservedForIssuance", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "zyme_MaximumNumberOfCommonSharesReservedForIssuanceIncreaseInPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maximum number of common shares reserved for issuance increase in percentage.", "label": "Maximum Number Of Common Shares Reserved For Issuance Increase In Percentage", "terseLabel": "Maximum number of common shares reserved for issuance increase in percentage" } } }, "localname": "MaximumNumberOfCommonSharesReservedForIssuanceIncreaseInPercentage", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "zyme_MerckSharpAndDohmeResearchLtdMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Merck sharp and dohme research ltd.", "label": "Merck Sharp and Dohme Research Ltd. [Member]", "terseLabel": "Merck Sharp and Dohme Research Ltd." } } }, "localname": "MerckSharpAndDohmeResearchLtdMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail", "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsScheduleOfCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetail" ], "xbrltype": "domainItemType" }, "zyme_OfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Offering.", "label": "Offering [Member]", "terseLabel": "Offering" } } }, "localname": "OfferingMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "zyme_OperatingLeaseRightOfUseAssetAmortizationAndImpairment": { "auth_ref": [], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating lease right of use asset amortization and impairment", "label": "Operating Lease Right Of Use Asset Amortization And Impairment", "terseLabel": "Amortization and impairment of operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationAndImpairment", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "zyme_OtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Others.", "label": "Other [Member]", "terseLabel": "Other" } } }, "localname": "OtherMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsScheduleOfCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetail" ], "xbrltype": "domainItemType" }, "zyme_OtherProductMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Product", "label": "Other Product [Member]", "terseLabel": "Research support and drug supply payments" } } }, "localname": "OtherProductMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsScheduleOfCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetail" ], "xbrltype": "domainItemType" }, "zyme_PaymentsOfDeferredFinancingFees": { "auth_ref": [], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments Of Deferred Financing Fees", "label": "Payments Of Deferred Financing Fees", "negatedLabel": "Deferred financing fees" } } }, "localname": "PaymentsOfDeferredFinancingFees", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "zyme_PerformanceMilestoneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Performance Milestone [Member]", "label": "Performance Milestone [Member]", "terseLabel": "Milestone revenue" } } }, "localname": "PerformanceMilestoneMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail", "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsScheduleOfCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetail" ], "xbrltype": "domainItemType" }, "zyme_PreFundedWarrantsIssuedInLieuOfCommonShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pre funded warrants issued in lieu of common shares to underwriters.", "label": "Pre Funded Warrants Issued In Lieu Of Common Shares", "terseLabel": "Pre funded warrants issued in lieu of common shares to underwriters (in shares)" } } }, "localname": "PreFundedWarrantsIssuedInLieuOfCommonShares", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "zyme_ProceedsFromIssuanceOfCommonStockPublicOffering": { "auth_ref": [], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from issuance of common stock public offering.", "label": "Proceeds From Issuance Of Common Stock Public Offering", "verboseLabel": "Proceeds from public offering, net of issuance costs (note 8a)" } } }, "localname": "ProceedsFromIssuanceOfCommonStockPublicOffering", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "zyme_ProceedsFromIssuanceOfSharesUnderEmployeeSharePurchasePlan": { "auth_ref": [], "calculation": { "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based compensation arrangement. Issuance includes, but is not limited to, employee share purchase plan.", "label": "Proceeds from Issuance of Shares Under Employee Share Purchase Plan", "terseLabel": "Issuance of common shares through employee stock purchase plan" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderEmployeeSharePurchasePlan", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "zyme_ReclassificationToLiabilityFromEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Reclassification to Liability from Equity", "label": "Reclassification To Liability From Equity", "terseLabel": "Reclassification to liabilities from equity" } } }, "localname": "ReclassificationToLiabilityFromEquity", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofChangesinFairValueofLiabilityClassifiedStockOptionsDetail" ], "xbrltype": "monetaryItemType" }, "zyme_ScheduleOfChangeInFairValueOfLiabilityClassifiedStockOptionsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of change in fair value of liability classified stock options.", "label": "Schedule Of Change In Fair Value Of Liability Classified Stock Options[Table Text Block]", "terseLabel": "Schedule of Changes in Fair Value of Liability Classified Stock Options" } } }, "localname": "ScheduleOfChangeInFairValueOfLiabilityClassifiedStockOptionsTableTextBlock", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "zyme_ScheduleOfLeaseLiabilitiesClassificationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of lease liabilities classification.", "label": "Schedule of Lease Liabilities Classification [Table Text Block]", "terseLabel": "Schedule of Balance Sheet Classification of Lease Liabilities" } } }, "localname": "ScheduleOfLeaseLiabilitiesClassificationTableTextBlock", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "zyme_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Grant Date Fair Value", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Grant Date Fair Value", "terseLabel": "Grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "zyme_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisablePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award exercisable period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Exercisable Period", "terseLabel": "Options granted under original plan exercisable period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisablePeriod", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "zyme_ShareBasedCompensationByShareBasedPaymentAwardUnamortizedCompensationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share based compensation by share based payment award unamortized compensation expense.", "label": "Share Based Compensation By Share Based Payment Award Unamortized Compensation Expense", "terseLabel": "Unamortized compensation expense related to unvested options" } } }, "localname": "ShareBasedCompensationByShareBasedPaymentAwardUnamortizedCompensationExpense", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "zyme_ShareBasedCompensationExpenseAndIncreaseDecreaseInFairValueOfLiabilityClassedEquityInstruments": { "auth_ref": [], "calculation": { "http://www.zymeworks.com/role/ShareholdersEquityScheduleofStockbasedCompensationExpenseforEquityClassifiedInstrumentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share Based Compensation Expense And Increase (Decrease) In Fair Value Of Liability Classed Equity Instruments", "label": "Share Based Compensation Expense And Increase (Decrease) In Fair Value Of Liability Classed Equity Instruments", "totalLabel": "Stock based compensation for equity classed instruments and change in fair value of liability classed equity instruments" } } }, "localname": "ShareBasedCompensationExpenseAndIncreaseDecreaseInFairValueOfLiabilityClassedEquityInstruments", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityScheduleofStockbasedCompensationExpenseforEquityClassifiedInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "zyme_ShortTermGuaranteedInvestmentCertificatesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Short-term Guaranteed Investment Certificates", "label": "Short-term Guaranteed Investment Certificates [Member]", "terseLabel": "Short-term GICs" } } }, "localname": "ShortTermGuaranteedInvestmentCertificatesMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "zyme_ShortTermInvestmentsMaturityTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Short term investments maturity term.", "label": "Short Term Investments Maturity Term", "terseLabel": "Short-term investments maturity term" } } }, "localname": "ShortTermInvestmentsMaturityTerm", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "zyme_USDollarsUnderTheNewStockOptionPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Us dollars under the new stock option plan.", "label": "U S dollars under the New Stock Option Plan [Member]", "verboseLabel": "U.S Dollar Under the New Option Stock Plan" } } }, "localname": "USDollarsUnderTheNewStockOptionPlanMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail", "http://www.zymeworks.com/role/ShareholdersEquityScheduleofEstimatedFairValueofStockOptionsAssumptionsDetail", "http://www.zymeworks.com/role/ShareholdersEquitySummaryofStockOptionsGrantedDetail" ], "xbrltype": "domainItemType" }, "zyme_UnrealizedForeignCurrencyLossGainLiabilityClassifiedStockOptions": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrealized foreign currency loss (gain) liability classified stock options.", "label": "Unrealized Foreign Currency Loss (Gain) Liability Classified Stock Options", "terseLabel": "Unrealized foreign currency loss (gain)" } } }, "localname": "UnrealizedForeignCurrencyLossGainLiabilityClassifiedStockOptions", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/FinancialInstrumentsScheduleofChangesinFairValueofLiabilityClassifiedStockOptionsDetail" ], "xbrltype": "monetaryItemType" }, "zyme_UpFrontTechnologyAccessFeeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Up-front Technology Access Fee", "label": "Up-front Technology Access Fee [Member]", "verboseLabel": "Up-front Technology Access Fee" } } }, "localname": "UpFrontTechnologyAccessFeeMember", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsAdditionalInformationStrategicPartnershipRevenueDetail", "http://www.zymeworks.com/role/ResearchCollaborationandLicensingAgreementsScheduleOfCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetail" ], "xbrltype": "domainItemType" }, "zyme_WarrantsIssuedPricePerPreFundedWarrant": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Warrants issued price per pre funded warrant.", "label": "Warrants Issued Price Per Pre Funded Warrant", "terseLabel": "Warrants issued price (in dollars per share)" } } }, "localname": "WarrantsIssuedPricePerPreFundedWarrant", "nsuri": "http://www.zymeworks.com/20200630", "presentation": [ "http://www.zymeworks.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r101": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "http://asc.fasb.org/topic&trid=2197064" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r119": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r169": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888369&loc=SL77918431-209957" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r238": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r239": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r241": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r242": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r243": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(4))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r76": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562" }, "r97": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r98": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "http://asc.fasb.org/topic&trid=75115024" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" } }, "version": "2.1" }